Biomarker & Intervention Discovery

Atherosclerosis

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
Gap size
Primary barrier
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

ACTA2 0APOB 102CRP 8IL6 173LDLR 48NOS3 0PCSK9 170TET2 68

Pipeline results not yet available for this target. Run the pipeline to populate.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
DEXAMETHASONE ? unclear Mechanistic
L-644,698 activates Mechanistic
INCLISIRAN ? unclear Mechanistic
REVERSE TRANSCRIPTASE INHIBITOR ? unclear Mechanistic
ZK118182 activates Mechanistic
RS 93520 activates Mechanistic
RIVAROXABAN ? unclear Mechanistic
ONO-AE3-237 inhibits Mechanistic
ALPROSTADIL activates Mechanistic
Δ12-PGJ2 activates Mechanistic
DINOPROSTONE activates Mechanistic
PGJ2 activates Mechanistic
LOVASTATIN ? unclear Mechanistic
SQ-27986 activates Mechanistic
TG11-77 inhibits Mechanistic
FENOFIBRATE MICRONIZED ? unclear Mechanistic
CLOPROSTENOL activates Mechanistic
U46619 activates Mechanistic
TG6-129 inhibits Mechanistic
APIXABAN ? unclear Mechanistic
DEHYDRATED ALCOHOL ? unclear Mechanistic
BWA868C inhibits Mechanistic
ZK110841 activates Mechanistic
MIPOMERSEN ? unclear Mechanistic
CHOLESTYRAMINE RESIN ? unclear Mechanistic
EPIGALLOCATECHIN GALLATE ? unclear Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
DINOPROST activates Mechanistic
[3H]BWA868C inhibits Mechanistic
HEPARIN ? unclear Mechanistic
S-5751 inhibits Mechanistic
PRAVASTATIN SODIUM ? unclear Mechanistic
BW 245C activates Mechanistic
LOMITAPIDE MESYLATE ? unclear Mechanistic
L-888,291 activates Mechanistic
QUERCETIN ? unclear Mechanistic
AH6809 inhibits Mechanistic
15-DEOXY-Δ12,14-PGJ2 activates Mechanistic
TRIFLUOPERAZINE ? unclear Mechanistic
PGD2 activates Mechanistic

Showing top 40 of 102 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
JNJ1661010 inhibits Mechanistic
ADALIMUMAB ? unclear Mechanistic
LY2077855 inhibits Mechanistic
OL135 inhibits Mechanistic
WARFARIN ? unclear Mechanistic
ASP8477 inhibits Mechanistic
URB597 inhibits Mechanistic
ROSUVASTATIN ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CISPLATIN ? unclear Mechanistic
ZILTIVEKIMAB ~ modulates Mechanistic
CHINESE HERBS ? unclear Mechanistic
PF-04236921 inhibits Mechanistic
MRA 003 US inhibits Mechanistic
SIGNAL TRANSDUCTION INHIBITOR ? unclear Mechanistic
BINETRAKIN ? unclear Mechanistic
IBUDILAST ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
SILTUXIMAB inhibits Mechanistic
METRONIDAZOLE ? unclear Mechanistic
CLAZAKIZUMAB inhibits Mechanistic
GALLIUM NITRATE ? unclear Mechanistic
INTERFERON ALFA-2B ? unclear Mechanistic
DULOXETINE HYDROCHLORIDE ? unclear Mechanistic
MEDI-5117 inhibits Mechanistic
GEMFIBROZIL ? unclear Mechanistic
BIAFINE CREAM ? unclear Mechanistic
ETANERCEPT ? unclear Mechanistic
ELSILIMOMAB inhibits Mechanistic
SAQUINAVIR ? unclear Mechanistic
INFLIXIMAB ? unclear Mechanistic
LINEZOLID ? unclear Mechanistic
IFOSFAMIDE ? unclear Mechanistic
OLOKIZUMAB inhibits Mechanistic
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
SELENIUM ? unclear Mechanistic
SIRUKUMAB inhibits Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
ECHINACEA PREPARATION ? unclear Mechanistic
ENZYME INHIBITOR ? unclear Mechanistic
FENOFIBRATE MICRONIZED ? unclear Mechanistic
VITAMIN K ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
RIBAVIRIN ? unclear Mechanistic
VITAMIN A PALMITATE ? unclear Mechanistic
ARSENIC TRIOXIDE ? unclear Mechanistic
DIHYDROSPHINGOSINE ? unclear Mechanistic
LEVOFLOXACIN ANHYDROUS ? unclear Mechanistic

Showing top 40 of 173 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
GLUCAGON (RDNA) ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
VITAMIN A ? unclear Mechanistic
COLESTIPOL HYDROCHLORIDE ? unclear Mechanistic
HEPARIN CALCIUM ? unclear Mechanistic
CHEMBL:CHEMBL233611 ? unclear Mechanistic
TRIBUTYRIN ? unclear Mechanistic
RECOMBINANT TRANSFORMING GROWTH FACTOR ? unclear Mechanistic
CHOLESTYRAMINE RESIN ? unclear Mechanistic
GEMFIBROZIL ? unclear Mechanistic
EPOETIN ALFA ? unclear Mechanistic
TETRACYCLINE ? unclear Mechanistic
HALOPERIDOL DECANOATE ? unclear Mechanistic
MIPOMERSEN ? unclear Mechanistic
PHYTOESTROGEN ? unclear Mechanistic
ANTIVIRAL AGENT ? unclear Mechanistic
FAT EMULSION ? unclear Mechanistic
VERAPAMIL ? unclear Mechanistic
LOMITAPIDE MESYLATE ? unclear Mechanistic
SOY PROTEIN ISOLATE ? unclear Mechanistic
ANTIBIOTIC ? unclear Mechanistic
BUTYRIC ACID ? unclear Mechanistic
ACTH ? unclear Mechanistic
ALIROCUMAB ? unclear Mechanistic
INCLISIRAN ? unclear Mechanistic
LOVASTATIN ? unclear Mechanistic
ACETYLCYSTEINE ? unclear Mechanistic
ROSUVASTATIN ? unclear Mechanistic
PRAVASTATIN SODIUM ? unclear Mechanistic
EVINACUMAB ? unclear Mechanistic
CHEMBL114890 activates Mechanistic 700.0 nM (EC50)
CHEMBL114705 activates Mechanistic 1200.0 nM (EC50)
CHEMBL115304 activates Mechanistic 1300.0 nM (EC50)
CHEMBL324616 activates Mechanistic 700.0 nM (EC50)
CHEMBL115205 activates Mechanistic 4000.0 nM (EC50)
CHEMBL112449 activates Mechanistic 1000.0 nM (EC50)
CHEMBL419400 activates Mechanistic 7000.0 nM (EC50)
CHEMBL419763 activates Mechanistic 1700.0 nM (EC50)
CHEMBL419042 activates Mechanistic 2000.0 nM (EC50)

Showing top 40 of 48 agents ranked by evidence tier.

Pipeline results not yet available for this target. Run the pipeline to populate.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
ALIROCUMAB inhibits Mechanistic
ONGERICIMAB inhibits Mechanistic
TAFOLECIMAB inhibits Mechanistic
LOMITAPIDE MESYLATE ? unclear Mechanistic
EVOLOCUMAB inhibits Mechanistic
RG-7652 inhibits Mechanistic
BOCOCIZUMAB inhibits Mechanistic
FROVOCIMAB ? unclear Mechanistic
RALPANCIZUMAB inhibits Mechanistic
LERODALCIBEP inhibits Mechanistic
INCLISIRAN ? unclear Mechanistic
INCLISIRAN SODIUM ? unclear Mechanistic
DIPHENYL BORINIC ACID inhibits Mechanistic 30000.0 nM (Ki)
PHENYL BUTYL BORINIC ACID inhibits Mechanistic 1000.0 nM (Ki)
CHEMBL4107804 inhibits Mechanistic 3200.0 nM (IC50)
CHEMBL4107907 inhibits Mechanistic 1700.0 nM (IC50)
CHEMBL4114159 inhibits Mechanistic 800.0 nM (IC50)
CHEMBL4108338 inhibits Mechanistic 1500.0 nM (IC50)
CHEMBL4107714 inhibits Mechanistic 1500.0 nM (IC50)
CHEMBL4110311 inhibits Mechanistic 9500.0 nM (IC50)
CHEMBL4107559 inhibits Mechanistic 1800.0 nM (IC50)
CHEMBL4114106 inhibits Mechanistic 1500.0 nM (IC50)
CHEMBL4109097 inhibits Mechanistic 11700.0 nM (IC50)
CHEMBL4108330 inhibits Mechanistic 2300.0 nM (IC50)
CHEMBL4109114 inhibits Mechanistic 4500.0 nM (IC50)
CHEMBL3961039 inhibits Mechanistic 7300.0 nM (IC50)
CHEMBL4112247 inhibits Mechanistic 10700.0 nM (IC50)
CHEMBL4109308 inhibits Mechanistic 800.0 nM (IC50)
CHEMBL4109014 inhibits Mechanistic 11820.0 nM (IC50)
CHEMBL4108567 inhibits Mechanistic 3800.0 nM (IC50)
CHEMBL4111131 inhibits Mechanistic 18000.0 nM (IC50)
CHEMBL4115372 inhibits Mechanistic 1700.0 nM (IC50)
CHEMBL4106481 inhibits Mechanistic 3050.0 nM (IC50)
CHEMBL4108186 inhibits Mechanistic 5610.0 nM (IC50)
CHEMBL4115360 inhibits Mechanistic 5800.0 nM (IC50)
CHEMBL4114503 inhibits Mechanistic 25300.0 nM (IC50)
CHEMBL4108540 inhibits Mechanistic 2970.0 nM (IC50)
CHEMBL4109409 inhibits Mechanistic 5750.0 nM (IC50)
CHEMBL4109932 inhibits Mechanistic 14300.0 nM (IC50)
CHEMBL4106569 inhibits Mechanistic 16800.0 nM (IC50)

Showing top 40 of 170 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
SELINEXOR ? unclear Mechanistic
AZACITIDINE ? unclear Mechanistic
RITUXIMAB ? unclear Mechanistic
QUIZARTINIB ? unclear Mechanistic
TALAZOPARIB ? unclear Mechanistic
HYDROCHLOROTHIAZIDE ? unclear Mechanistic
ELTANEXOR ? unclear Mechanistic
OLAPARIB ? unclear Mechanistic
DASATINIB ANHYDROUS ? unclear Mechanistic
VEMURAFENIB ? unclear Mechanistic
DOXORUBICIN HYDROCHLORIDE ? unclear Mechanistic
HYDROXYUREA ? unclear Mechanistic
CHEMBL4457636 inhibits Mechanistic 73000.0 nM (IC50)
CHEMBL4872206 inhibits Mechanistic 1200.0 nM (IC50)
N-OXALYLGLYCINE inhibits Mechanistic 19700.0 nM (IC50)
CHEMBL4851104 inhibits Mechanistic 9400.0 nM (IC50)
CHEMBL4855677 inhibits Mechanistic 54800.0 nM (IC50)
CHEMBL4872110 inhibits Mechanistic 11000.0 nM (IC50)
CHEMBL4860506 inhibits Mechanistic 10500.0 nM (IC50)
CHEMBL4870693 inhibits Mechanistic 3420.0 nM (Kd)
CHEMBL4859276 inhibits Mechanistic 2050.0 nM (Kd)
DEFEROXAMINE inhibits Mechanistic 46000.0 nM (IC50)
CHEMBL5193408 inhibits Mechanistic 13000.0 nM (IC50)
CHEMBL5205660 inhibits Mechanistic 2300.0 nM (IC50)
CHEMBL5199439 inhibits Mechanistic 86600.0 nM (IC50)
CHEMBL5177215 inhibits Mechanistic 23900.0 nM (IC50)
CHEMBL1230640 inhibits Mechanistic 2270.0 nM (IC50)
CHEMBL316034 inhibits Mechanistic 5128.61 nM (IC50)
CHEMBL3646117 inhibits Mechanistic 18620.87 nM (IC50)
CHEMBL4475458 inhibits Mechanistic 5495.41 nM (IC50)
VADADUSTAT inhibits Mechanistic 5011.87 nM (IC50)
CHEMBL1982368 inhibits Mechanistic 3019.95 nM (IC50)
CHEMBL1398529 inhibits Mechanistic 1548.82 nM (IC50)
PANOBINOSTAT inhibits Mechanistic 3801.89 nM (IC50)
CHEMBL1615211 inhibits Mechanistic 12882.5 nM (IC50)
CHEMBL1614745 inhibits Mechanistic 15488.17 nM (IC50)
CHEMBL92309 activates Mechanistic 11481.54 nM (EC50)
CHEMBL5527999 inhibits Mechanistic 250.0 nM (IC50)
CHEMBL5565375 inhibits Mechanistic 250.0 nM (IC50)
CHEMBL5557372 inhibits Mechanistic 23988.33 nM (IC50)

Showing top 40 of 68 agents ranked by evidence tier.


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.

NCT01778569 Phase: N/A Started: 2013-01-22

Background: \- Cardiometabolic diseases are medical disorders that can occur together and affect the heart. They increase the risk of developing heart disease and diabetes. One disorder, psoriasis, is an inflammation that mostly affects the skin but can affect the entire body. Another disorder, ath...

NCT00353782 Phase: N/A Started: 2003-10-14

This study will evaluate people with dyslipidemias - disorders that affect the fat content in the blood. Fats, or lipids, such as cholesterol and triglycerides, are carried in the blood in particles called lipoproteins. These particles are involved in causing blood vessel diseases that can lead to c...

NCT07144150 Phase: NA Started: 2026-04-17

The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon \[DCB\]) in the treatment of the femoropopliteal artery l...

NCT02311335 Phase: N/A Started: 2014-11-26

Background: \- Genes are the instructions our body uses to function. Researchers can look for changes, or variants, in the genes. The goal of this study is to find new gene changes that lead to lipid disorders. Older research methods looked at one or a few genes at a time. Genomic sequencing looks ...

NCT07000357 Phase: PHASE3 Started: 2025-06-04

The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs pl...

NCT06544135 Phase: N/A Started: 2025-04-14

This is a preliminary prospective observational study measuring change in lower extremity temperature in response to revascularization procedure. The main question this study aims to answer is: \- Are temperature measurements from a forward looking infrared (FLIR) camera of the lower extremity use...

NCT00001204 Phase: N/A Started: 1992-01-07

Homozygous familial hypercholesterolemia is a rare inherited disease of metabolism. It occurs in less than 1 in 1 million people within the United States. Patients with the disease are typically children and young adults who develop heart disease early in life. Children less than age 5 years with th...

NCT07448038 Phase: PHASE2 Started: 2026-06-05

The main purpose of the study is to evaluate the efficacy of selnoflast compared with placebo in participants with atherosclerosis, at high-risk for major adverse cardiovascular event (MACE), who are currently on standard-of-care (SOC) therapy.

NCT07465627 Phase: N/A Started: 2026-07

Chronic limb threatening ischemia (CLTI) represents the most advanced stage of peripheral arterial disease (PAD) and is characterized by ischemic rest pain, non-healing wounds, or ischemic gangrene. High-risk PAD populations including patients with end-stage renal disease and or diabetes also experi...

NCT06676280 Phase: PHASE4 Started: 2025-07-24

The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent atherosclerotic cardiovascular disease (ASCVD) events with severe coronary calcific...

NCT05906797 Phase: NA Started: 2020-09-07

A double-blind randomized-controlled clinical trial is conducted in order to evaluate the impact of non-surgical periodontal treatment on endothelial dysfunction parameters in subjects with periodontitis and without any cardiovascular disease.

NCT04800276 Phase: NA Started: 2021-02-11

The prevalence of peripheral arterial disease is 12.2% in France. Intermittent claudication is the most common symtom of this disease. During physical exercise, such as walking, blood oxygen (O2) requirements increase. The development of atherosclerosis in the lower limbs, causes narrowing of the ar...

NCT01143454 Phase: N/A Started: 2010-07-21

Background: \- Researchers are interested in studying individuals who have known or suspected metabolic, inflammatory or genetic diseases that may put them at a high risk for heart diseases or diseases of their blood vessels. Depending on the condition being studied, both affected and nonaffected i...

NCT03982693 Phase: PHASE3 Started: 2019-03-19

TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.

NCT06813339 Phase: EARLY_PHASE1 Started: 2025-02-25

The goal of this clinical trial is to learn if UDP-003 is safe in healthy human participants and patients, assess the pharmacokinetics (PK)/pharmacodynamics (PD) of UDP-003 in healthy human participants and patients and its potential efficacy in patients. Researchers will compare UDP-003 to a place...


Agents Found By Disease-Level Search

Searched directly from “Atherosclerosis” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.